XOMA Royalty (XOMA) Cash from Operations Growth (3y) (2013 - 2026)
XOMA Royalty (XOMA) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 48.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.02% |
| Dec 31, 2025 | -12.24% |
| Jun 30, 2025 | 51.81% |
| Mar 31, 2025 | 61.07% |
| Dec 31, 2024 | -27.95% |
| Sep 30, 2024 | -41.03% |
| Jun 30, 2024 | 39.01% |
| Mar 31, 2024 | -75.58% |
| Dec 31, 2023 | -30.49% |
| Sep 30, 2023 | 4.84% |
| Jun 30, 2023 | -35.93% |
| Mar 31, 2023 | -29.26% |
| Dec 31, 2022 | 2.12% |
| Sep 30, 2022 | -43.65% |
| Jun 30, 2022 | -11.76% |
| Mar 31, 2022 | -32.37% |
| Dec 31, 2021 | 136.92% |
| Sep 30, 2021 | -3.87% |
| Jun 30, 2021 | -5.88% |
| Mar 31, 2021 | 38.02% |